OLIGOMERIX, Inc. Announces Board Changes: Vic Micati Appointed Chairman and Jack Pasini Appointed Company Director and Chief Commercial Officer
NEW YORK, Oct. 13 /PRNewswire/ -- OLIGOMERIX, Inc. announced today that Vic Micati, a Director since 2007, has been appointed Chairman of Oligomerix and that Jack Pasini has been appointed to the Company's Board of Directors and as Chief Commercial Officer.
Having worked at Pfizer Inc. (PFE) for nearly 40 years, Mr. Micati was a member of Pfizer's Corporate Management Committee responsible for all aspects of global operations. He also served as Executive Vice President of the Pharmaceutical Group and Vice President of Pfizer Inc. He was appointed to the International Board of Directors in 1984 and became President of Pfizer's European operations in 1990.
Since 1999, Mr. Micati has worked as a consultant in the pharmaceutical industry and served on the board of several companies including Ilex Oncology (ILXO), subsequently acquired by Genzyme Corporation (GENZ), ENZON Pharmaceuticals Inc. (ENZN) and was member of the Advisory Board of Almirall, a Spanish pharmaceutical company.
Mr. Pasini is also a seasoned executive, having gained broad global commercial leadership experience during a 30-year career with Pfizer. Formerly, Mr. Pasini was Vice President, Worldwide Marketing responsible for Pfizer's Anti-Infective and Allergy/Respiratory Therapeutic Groups. He also served as Vice President of Product Development, Regional President of the Africa, Middle East Region, and Vice President of Business Intelligence & Planning. Mr. Pasini served on the board of the American Lung Association of the City of New York for five years. Since his retirement in 2007, Mr. Pasini has worked as a consultant in the pharmaceutical industry.
"We are very pleased that Vic has agreed to take on the role of Chairman of Oligomerix and that Jack has agreed to join the Oligomerix Board and serve as Chief Commercial Officer. We anticipate that Jack will play a key role in developing important partnerships within the industry to facilitate our transition into a full-scale biotechnology company," said James Moe, President & CEO.
OLIGOMERIX, Inc. is a biopharmaceutical company founded in 2006 located within the Audubon Biomedical Science and Technology Park of Columbia University. The Company is exploiting its novel research that allows rapid generation of stable amyloid oligomers as targets for drug discovery. These systems will enable target identification and validation, and drug discovery for Alzheimer's and other neurodegenerative diseases. For more information visit www.oligomerix.com.